MOUNJARO KWIKPEN 7.5MG/0.6ML 2.4ML X1

Indications

Approved Uses

Type 2 diabetes mellitus in adults: as an adjunct to diet and exercise to improve glycemic control.

Dosage & Administration

Dosing by Condition

Type 2 diabetes (adults): 2.5 mg SC once weekly for 4 weeks (initiation dose), then 5 mg once weekly; if additional control needed, increase by 2.5 mg increments after at least 4 weeks on the current dose to 7.5 mg, 10 mg, 12.5 mg, or max 15 mg once weekly.

Initial Dose

2.5 mg subcutaneously once weekly for 4 weeks (this dose is for treatment initiation and not for glycemic control).

Maintenance Dose

After 4 weeks on the 2.5 mg dose, increase the dosage to 5 mg subcutaneously once weekly. After at least 4 weeks on the 5 mg dose, the dose can be increased to 7.5 mg, 10 mg, 12.5 mg, or 15 mg subcutaneously once weekly.

Maximum Dose

Maximum 15 mg subcutaneously once weekly.

Children's Dosage

Approved for pediatric patients 10 years of age and older with type 2 diabetes mellitus.

Dose Adjustment Notes

Titrate in 2.5 mg steps no more frequently than every 4 weeks based on tolerability and glycemic needs; when used with insulin or a sulfonylurea, consider reducing the insulin/sulfonylurea dose to lower hypoglycemia risk; no dosage adjustment is required for renal or hepatic impairment.

How to Take

For subcutaneous injection only. Inject once weekly on the same day each week, at any time of day, with or without meals, into the abdomen, thigh, or upper arm; rotate injection sites and do not inject into areas that are tender, bruised, red, or hard. If a dose is missed, administer as soon as possible within 4 days (96 hours) after the missed dose; if more than 4 days have passed, skip the missed dose and resume the regular once-weekly schedule. When used with insulin, administer as separate injections and do not mix.

How to Prepare

Ready-to-use pre-filled pen (no reconstitution/dilution); visually inspect solution (clear, colorless to slightly yellow) and do not use if discolored/particulate; attach a new needle and administer subcutaneously per manufacturer instructions

Side Effects

Common Side Effects

Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia/indigestion, and abdominal pain; injection-site reactions can also occur.

Side Effect Frequency

Very common (≥10%): nausea, diarrhea, decreased appetite, vomiting, constipation. Common (1-10%): abdominal pain, dyspepsia, injection site reactions, fatigue, hypoglycemia (with insulin or sulfonylurea), eructation, flatulence, gastroesophageal reflux.

Safety & Warnings

Contraindications

Personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), known serious hypersensitivity to tirzepatide or its excipients.

Warnings & Precautions

Key warnings/precautions: thyroid C-cell tumor risk-contraindicated with personal/family history of MTC or MEN2; pancreatitis-discontinue if suspected (do not restart if confirmed); hypoglycemia risk with insulin/secretagogues; severe GI adverse reactions and dehydration leading to AKI-advise hydration/monitor renal function; gallbladder disease; hypersensitivity reactions-discontinue if serious; diabetic retinopathy complications in at-risk patients; not for type 1 diabetes or DKA and not a substitute for insulin.

Age Restriction

Approved for use in patients 10 years of age and older with type 2 diabetes mellitus.

Drug Interactions

Drug Interactions

Major: increased hypoglycemia risk with insulin and insulin secretagogues (e.g., sulfonylureas) - consider dose reduction. Delays gastric emptying and may reduce exposure of oral contraceptives - use alternative/backup contraception for 4 weeks after initiation and for 4 weeks after each dose escalation. May affect absorption of other oral drugs (use caution with narrow therapeutic index agents such as warfarin/digoxin; monitor as appropriate). Avoid combining with other GLP-1 receptor agonists due to overlapping effects.

Interaction Severity

MAJOR/clinically significant: insulin and insulin secretagogues (e.g., sulfonylureas) due to increased hypoglycemia risk-consider dose reduction and monitor; MODERATE: oral contraceptives (reduced exposure due to delayed gastric emptying-use alternative/backup contraception for 4 weeks after initiation and after each dose escalation) and other oral drugs where delayed absorption is clinically important; warfarin is not a consistent major interaction but INR monitoring is prudent when glycemic control/weight changes or GI effects occur.

Food Interaction

No food restrictions; may be administered with or without meals.

Special Populations

Pregnancy

Consult Doctor

Breastfeeding

Consult Doctor

Children

Approved for pediatric patients 10 years of age and older with type 2 diabetes mellitus.

Elderly

Standard adult dosing - no dose adjustment required based on age alone; titrate based on tolerability

Kidney Impairment

No dose adjustment required for any degree of renal impairment, including end-stage renal disease; monitor renal function if severe GI reactions occur (dehydration/AKI risk).

Liver Impairment

No dose adjustment required in hepatic impairment (mild, moderate, or severe).

Storage & Patient Advice

Storage Conditions

store in a refrigerator (2°c - 8°c)

Preparation Instructions

Ready-to-use pre-filled pen (no reconstitution/dilution); visually inspect solution (clear, colorless to slightly yellow) and do not use if discolored/particulate; attach a new needle and administer subcutaneously per manufacturer instructions

Missed Dose

If a dose is missed, administer as soon as possible within 4 days (96 hours) of the missed dose. If more than 4 days have passed, skip the missed dose and resume on the next regularly scheduled day. Do not administer two doses within 3 days of each other

Stopping the Medicine

Can be stopped without tapering, but should be done in consultation with the prescriber because glycemic control (and weight) may worsen after discontinuation.

Overdose

Expected symptoms: severe GI effects (nausea/vomiting) and hypoglycemia (especially with insulin/sulfonylureas). Management: supportive care, monitor glucose, treat hypoglycemia with carbohydrates/IV dextrose as needed; no specific antidote-seek urgent medical care/poison center.

Patient Counseling

Inject once weekly on the same day each week (with or without food) into abdomen/thigh/upper arm and rotate sites; if a dose is missed, take within 4 days (96 hours) or skip and resume-do not take doses within 3 days of each other; store refrigerated 2-8°C and do not freeze; counsel on common GI effects and hydration, hypoglycemia risk when combined with insulin/sulfonylurea, and to seek care for severe/persistent abdominal pain (pancreatitis) or symptoms of gallbladder disease; warn about thyroid C-cell tumor risk/contraindication in patients with personal/family history of medullary thyroid carcinoma or MEN2; advise backup contraception for 4 weeks after starting and after each dose increase if using oral contraceptives.

Monitoring Requirements

Monitor HbA1c periodically (typically every ~3 months until stable, then per clinical need), self-monitored blood glucose as appropriate (especially if used with insulin/sulfonylurea), weight, and tolerability; monitor for symptoms/signs of pancreatitis and gallbladder disease; assess renal function if significant GI losses/dehydration occur; monitor for diabetic retinopathy complications in patients with pre-existing retinopathy when glycemia improves rapidly.

Pharmacology

Mechanism of Action

A dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It increases insulin secretion, decreases glucagon secretion in a glucose-dependent manner, slows gastric emptying, and acts on brain centers to reduce appetite.

Onset of Action

Glucose-lowering can begin after the first dose (within the first week); maximal effect is reached over several weeks as the dose is titrated.

Duration of Effect

Approximately 1 week per dose (supports once-weekly dosing).

Half-Life

Approximately 5 days (120 hours)

Metabolism

Metabolized by proteolytic cleavage of the peptide backbone with beta-oxidation of the fatty diacid moiety and amide hydrolysis; not a CYP450 substrate.

Excretion

Eliminated primarily via proteolytic degradation with metabolites excreted in urine and feces; intact tirzepatide is not expected to be excreted unchanged to a meaningful extent.

Product Information

Available Dosage Forms

Solution for injection in single-dose pre-filled pen.

Composition per Dose

Each 0.5 mL dose contains 7.5 mg tirzepatide; excipients: sodium phosphate dibasic heptahydrate, sodium chloride, L-arginine hydrochloride, polysorbate 80, water for injection.

Generic Availability

No

OTC Alternatives

No OTC alternative

Diabetes Type

Type 2

Legal Disclaimer - Al Mujtama Pharmacy

The product information provided is derived from verified pharmaceutical references and is intended for general health education only. It is not a substitute for professional medical advice, diagnosis, or treatment.

Al Mujtama Pharmacy assumes no legal or medical liability for:

• Any therapeutic decision made based on the information displayed without consulting a licensed physician or pharmacist
• Any discrepancy between the information provided and the product's package insert or SFDA guidelines
• Any misuse of medication resulting from personal interpretation of the content displayed

Important notice: Drug formulations and instructions may vary between production batches. Always rely on the leaflet included inside the product packaging you have, and consult your pharmacist or physician before starting, adjusting, or discontinuing any medication.

By using this content, you acknowledge that you have read this disclaimer and agree that Al Mujtama Pharmacy bears no liability arising from reliance on this information as a substitute for direct medical consultation.

Your health is a trust - always consult your doctor first.